Table IV.
Multivariate analysis of prognostic factors of PFS following EOF treatment.
| PFS | |||
|---|---|---|---|
| Clinical characteristic | Hazard ratio | 95% CI | P-valuea |
| Pathological grade | |||
| Low and undifferentiated | 1 | 0.005 | |
| Moderate and high | 0.252 | 0.097–0.657 | |
| Unclassified | 0.633 | 0.382–1.046 | |
| No. of lesions | |||
| 1 | 1 | 0.020 | |
| 2 | 0.159 | 0.030–0.854 | |
| ≥3 | 0.952 | 0.300–3.025 | |
| Synchronous metastasis | |||
| Presence | 1 | 0.628 | |
| Absence | 1.184 | 0.597–2.348 | |
| MB rs7292 | |||
| CC | 1 | <0.001 | |
| CT+TT | 0.135 | 0.057–0.321 | |
| MLH1 rs9852810 | |||
| AA+AG | 1 | 0.024 | |
| GG | 0.494 | 0.267–0.913 | |
a
P-value is evaluated in patients without an unclassified pathological stage. PFS, progression-free survival; CI, confidence interval; MB, myoglobin; MLH1, MutL homolog 1.